Supporting the NHS to close the diagnostic gap in gynaecological health.
Supporting the NHS to close the diagnostic gap in gynaecological health.
Advancing evidence, enabling safe adoption and building long-term, sustainable partnerships.
1 in 3
Eligible women in the UK are not screened within the recommended timeframe
85%
Of UK women want a choice between self-sampling and clinic-based screening
70%
Prefer self-sampling at home over attending a clinic
Our work focuses on three core areas:
Supporting healthcare systems & commercial partners to adopt innovation safely
Our NHS partners
Our NHS partners
Working with health innovation networks across England to bring Daye's at-home diagnostics into clinical pathways.
Operation Model
A complimentary sampling option to fit the existing pathway
A complimentary sampling option to fit the existing pathway
No change to downstream clinical management (e.g. cytology).
1. Supporting the NHS to eradicate cervical cancer by 2040
We run structured ICB & PCN pilots, generate real-world evidence on uptake and clinical outcomes, and deliver the health economic case for adoption - modelled cost savings, uplift in screening uptake and reduced clinical resource burden.
1. Supporting the NHS to eradicate cervical cancer by 2040
We run structured ICB & PCN pilots, generate real-world evidence on uptake and clinical outcomes, and deliver the health economic case for adoption - modelled cost savings, uplift in screening uptake and reduced clinical resource burden.
1. Supporting the NHS to eradicate cervical cancer by 2040
We run structured ICB & PCN pilots, generate real-world evidence on uptake and clinical outcomes, and deliver the health economic case for adoption - modelled cost savings, uplift in screening uptake and reduced clinical resource burden.
2. Ongoing refinement to cervical screening uptake
We align with NSC, NICE and RCOG frameworks, integrate with existing cytology recall and colposcopy pathways, and meet NHS clinical governance standards. We are on the SBS framework and are endorsed by the NHS Innovation Accelerator.
2. Ongoing refinement to cervical screening uptake
We align with NSC, NICE and RCOG frameworks, integrate with existing cytology recall and colposcopy pathways, and meet NHS clinical governance standards. We are on the SBS framework and are endorsed by the NHS Innovation Accelerator.
2. Ongoing refinement to cervical screening uptake
We align with NSC, NICE and RCOG frameworks, integrate with existing cytology recall and colposcopy pathways, and meet NHS clinical governance standards. We are on the SBS framework and are endorsed by the NHS Innovation Accelerator.
3. Providing critical screening intelligence
We map screening coverage at ICB and PCN level, quantify the 1-in-3 unscreened gap against the NHS 80% target, and identify under-served cohorts where self-sampling has the greatest impact. We surface the data commissioners need to make the case for cost-effective, improved pathways.
3. Providing critical screening intelligence
We map screening coverage at ICB and PCN level, quantify the 1-in-3 unscreened gap against the NHS 80% target, and identify under-served cohorts where self-sampling has the greatest impact. We surface the data commissioners need to make the case for cost-effective, improved pathways.
3. Providing critical screening intelligence
We map screening coverage at ICB and PCN level, quantify the 1-in-3 unscreened gap against the NHS 80% target, and identify under-served cohorts where self-sampling has the greatest impact. We surface the data commissioners need to make the case for cost-effective, improved pathways.
“The Daye Diagnostic Tampon has significantly enhanced our ability to provide comprehensive gynecological care. Working with the Daye team has been an absolute pleasure. Their commitment to raising the standards in gynecological care aligns perfectly with Wisp's mission to increase access to vaginal healthcare.”
“The Daye Diagnostic Tampon has significantly enhanced our ability to provide comprehensive gynecological care. Working with the Daye team has been an absolute pleasure. Their commitment to raising the standards in gynecological care aligns perfectly with Wisp's mission to increase access to vaginal healthcare.”
“The Daye Diagnostic Tampon has significantly enhanced our ability to provide comprehensive gynecological care. Working with the Daye team has been an absolute pleasure. Their commitment to raising the standards in gynecological care aligns perfectly with Wisp's mission to increase access to vaginal healthcare.”
Daye is petroleum-plastic-free and carbon-neutral - helping the NHS deliver on its Net Zero commitment.
Daye is petroleum-plastic-free and carbon-neutral - helping the NHS deliver on its Net Zero commitment.
The Diagnostic Tampon was selected as the NHS Rewired Pitchfest 2026 winner.
Daye tampons are manufactured in accordance with medical device standards, including ISO13485 and GMP. The Vaginal Microbiome Testing Kit is intended for general wellness purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Test results provide information about your vaginal microbiome and should not be used to make medical decisions. Any mention of specific conditions or medical terms is for educational purposes only and does not constitute a medical diagnosis.
Daye tampons are manufactured in accordance with medical device standards, including ISO13485 and GMP. The Vaginal Microbiome Testing Kit is intended for general wellness purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Test results provide information about your vaginal microbiome and should not be used to make medical decisions. Any mention of specific conditions or medical terms is for educational purposes only and does not constitute a medical diagnosis.
Daye tampons are manufactured in accordance with medical device standards, including ISO13485 and GMP. The Vaginal Microbiome Testing Kit is intended for general wellness purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Test results provide information about your vaginal microbiome and should not be used to make medical decisions. Any mention of specific conditions or medical terms is for educational purposes only and does not constitute a medical diagnosis.
Our work focuses on three core areas:
Prioritise patient comfort
Supporting healthcare systems & commercial partners to adopt innovation safely
Building strategic partnerships that enable responsible, scalable growth
Our work focuses on three core areas:
Generating rigorous clinical and real-world evidence
Supporting healthcare systems & commercial partners to adopt innovation safely
Building strategic partnerships that enable responsible, scalable growth